Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Alvarez.
Thorax | 1995
Luis Valdés; David Alvarez; E. San Jose; J. R. G. Juanatey; Antonio Pose; José Manuel Valle; Marcelino Salgueiro; José Suárez
BACKGROUND--Pleural biopsy is usually considered important for the diagnosis of pleural effusions, especially for distinguishing between tuberculosis and neoplasia, even though tuberculous pleural fluid contains sensitive biochemical markers. In regions with a high prevalence of tuberculosis, and in patient groups with a low risk of other causes of pleurisy, the positive predictive value of these markers is increased. The criteria for performing a pleural biopsy under these circumstances have been investigated, using adenosine deaminase (ADA) as a pleural fluid marker for tuberculosis. METHODS--One hundred and twenty nine patients with a pleural effusion aged < or = 35 years (mean (SD) 25.2 (4.9) years) were studied. Seventy three were men. Eighty one effusions (62.8%) were tuberculous, 12 (9.3%) parapneumonic, and 10 (7.7%) neoplastic, five were caused by pulmonary thromboembolism, four by systemic lupus erythematosus, seven by empyema, three following surgery, one was the result of asbestosis, and one of nephrotic syndrome. In five cases no definitive diagnosis was reached. ADA levels were determined by the method of Galanti and Giusti. RESULTS--The diagnostic yield of procedures not involving biopsy was 94.5% (122/129). Pleural biopsy provided a diagnosis in a further two cases, but not in the remaining five. All tuberculous cases had pleural fluid levels of ADA of > 47 U/l (mean (SD) 111.1 (36.6) U/l). The only other cases in which ADA exceeded this level were six of the seven patients with empyema. Cytological examination of the pleural fluid diagnosed eight of the 10 neoplastic cases, compared with six diagnosed by pleural biopsy. CONCLUSIONS--In a region with a high prevalence of tuberculosis procedures not involving pleural biopsy have a very high diagnostic yield in patients with a pleural effusion aged < or = 35 years, making biopsy necessary only in cases in which pleural levels of ADA are below 47 U/l, pleural fluid cytology is negative and, in the absence of a positive basis for some other diagnosis, neoplasia is suspected.
Clinica Chimica Acta | 1997
M. Esther San José; David Alvarez; Luis Valdés; Alfredo Sarandeses; José Manuel Valle; Pedro Penela
Approximately 20% of pleural effusions are caused by neoplastic processes. Although cytology is the most specific routine diagnostic procedure, its sensitivity of 50-60% is insufficient, and thus diagnosis is usually carried out by more invasive techniques such as pleural biopsy, thoracoscopy or thoracotomy. The object of this study is to evaluate the use of determining some tumour markers in pleural fluid obtained by thoracocentesis for diagnosis of neoplastic pleural effusion. Patients (271) with pleural effusions were classified in five groups: I: neoplasms n = 88; II: tuberculosis n = 63; III: parapneumonics n = 53; IV: miscellaneous exudates n = 39 and V: transudates n = 28. The tumour markers studied were: carcinoembryonic antigen (CEA), CA 125, squamous cell carcinoma antigen (SCC), and neuron specific enolase (NSE). The tumour makers had the following diagnostic efficiencies for neoplastic origin of the pleural effusion: CEA 76% (sensitivity 31%, specificity 93%); CA 125 66% (70% and 61%); SCC 65% (48% and 80%) and NSE 53% (30% and 89%). The diagnostic efficiencies for pulmonary neoplastic origins were 68% for NSE (sensitivity 83%, specificity 53%); 65% for SCC (54% and 75%); 63% for CEA (80% and 48%) and 61% for CA 125 (79% and 42%). We believe that the routine testing of tumour markers in pleural fluid obtained by thoracocentesis would greatly increase diagnostic effectiveness and could avoid the practice of more aggressive diagnostic techniques on the patient.
Annals of Clinical Biochemistry | 1999
M. Esther San José; Luis Valdés; M Jesús Saavedra; Jesus M De Vega; David Alvarez; Juan Viñuela; Pedro Penela; José Manuel Valle; Rafael Seoane
Different systemic and local responses to mycobacterial antigens suggest an active compartmentalization of responsive lymphocytes to tubercular antigens. This fact, observed in pleuritic processes, raises doubts about the accuracy of information obtained in the study of cells taken solely from peripheral blood. For this reason we decided to study the concept of compartmentalization in 140 patients suffering from pleural effusions. Patients were classified into six groups according to the aetiology of the effusion: group I, tuberculous, n = 23; group II, paraneoplastic, n = 41; group III, metapneumonic empyematous, n = 5; group IV, transudate, n = 38; group V, miscellaneous exudate, n = 19; group VI, unknown aetiology, n = 14. In each group we studied the lymphocyte population by using flow cytometry with doubly fluorescent monoclonal antibodies: B [expressing human lymphocyte antigen (HLA)-DR on the surface], T (CD3 +), CD4 + and CD8 +, and the subpopulation of activated T lymphocytes (together expressing CD3 and HLA-DR on the surface) (CD3 + DR +). The study of these subpopulations in peripheral blood did not yield valuable results, but the CD3 + DR + population in pleural fluid demonstrated a diagnostic efficiency of 84% [positive predictive value (PPV) 51%, negative predictive value (NPV) 96%] at a cut-off value of 80.4 cells/mm3. The CD3 + DR + pleural fluid/peripheral blood ratio demonstrated an efficiency of 83% (PPV 50%, NPV 96%), and showed a statistically significant difference (P < 0·02) with regard to all the diagnostic groups, with the exception of the paraneoplastic effusions. The lymphocytic subpopulations study confirms the concept of compartmentalization in tuberculous pleuritis, as shown by the greater number of activated T lymphocytes present in pleural fluid in comparison with peripheral blood in tuberculous pleuritis, a 98% efficiency of adenosine deaminase (ADA) determination in pleural fluid versus a 50% value in peripheral blood, predominance of helper cells (CD4 +) in pleural fluid and suppressor cells (CD8 +) in peripheral blood, a greater CD4 + /CD8 + ratio in pleural fluid than in peripheral blood, and a significant correlation of ADA-CD3 + DR + in pleural fluid, which does not occur in peripheral blood.
Biochemical Pharmacology | 2008
Montserrat Buceta; Eduardo Domínguez; Marián Castro; José Antonio Fraiz Brea; David Alvarez; Javier Barcala; Luis Valdés; Pedro Álvarez-Calderón; Fernando Domínguez; Bernat Vidal; Jose-Luis Diaz; Montse Miralpeix; Jorge Beleta; María Isabel Cadavid; María Isabel Loza
Asthma is a chronic inflammatory disease of the airways that involves many cell types, amongst which mast cells are known to be important. Adenosine, a potent bronchoconstricting agent, exerts its ability to modulate adenosine receptors of mast cells thereby potentiating derived mediator release, histamine being one of the first mediators to be released. The heterogeneity of sources of mast cells and the lack of highly potent ligands selective for the different adenosine receptor subtypes have been important hurdles in this area of research. In the present study we describe compound C0036E08, a novel ligand that has high affinity (pK(i) 8.46) for adenosine A(2B) receptors, being 9 times, 1412 times and 3090 times more selective for A(2B) receptors than for A(1), A(2A) and A(3) receptors, respectively. Compound C0036E08 showed antagonist activity at recombinant and native adenosine receptors, and it was able to fully block NECA-induced histamine release in freshly isolated mast cells from human bronchoalveolar fluid. C0036E08 has been shown to be a valuable tool for the identification of adenosine A(2B) receptors as the adenosine receptors responsible for the NECA-induced response in human mast cells. Considering the increasing interest of A(2B) receptors as a therapeutic target in asthma, this chemical tool might provide a base for the development of new anti-asthmatic drugs.
Respiratory Medicine | 1998
Luis Valdés; J.R. González-Juanatey; David Alvarez; J. Antúnez; J. Manuel Valle; Pedro Penela; R. Álvarez-Sala
Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4’ T-lymphocytopenia. Ann Intern Med 1993: 119: 55-62. Beck JS, Potts RC, Kardjito T et al. T4 lymphopenia in patients with active tuberculosis. Clin E.xp Imrnonol 1985; 60: 49-54. Greenberg SD, Frager D, Suster B et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193: 116-119. Japan Health and Welfare Statistics Association. Health and Welfare Statistics, 1995 Tokyo, 1995 (in Japanese); Tokyo. Turett GS, Telzak EE. Normalization of CD4’ Tlymphocyte depletion in patients without HIV infection treated for tuberculosis. Chest 1994; 105: 1335-1337. Ho DD, Cao Y, Zhu T et al. Idiopathic CD4+ Tlymphocytopenia immunodeficiency without evidence of HIV infection. N Engl J Med 1993; 328: 380-385. Soriano V, Hewlett, I, Heredia A et al. Idiopathic CD4+ T-lymphocytopenia. Lancer 1992; 340: 607-608.
Scandinavian Journal of Clinical & Laboratory Investigation | 1993
M. E. San José; Alfredo Sarandeses; David Alvarez; Luis Valdés; B. Chomón; M. J. Del Rio
Iron levels in samples from certain treated tuberculous patients are underestimated by the Ferrochem II analyser. Of the tuberculostatic drugs examined for a possible interference, isoniazid, ethambutol, rifampicin, pyrazinamide and Rifater (a mixture of rifampicin, isoniazid and pyrazinamide), only pyrazinamide and Rifater (due to its pyrazinamide content) were associated with iron levels differing significantly (p < 0.001) from those of controls, with means of -317.2 and -185.6 mumol l-1 for pyrazinamide and Rifater respectively as against 9.91 mumol l-1 for the controls. The negative interference (I) due to pyrazinamide was independent of iron level in the samples but dependent on pyrazinamide concentration in the same (P) (r = 0.9993), I = -0.4380P-0.4276.
JAMA Internal Medicine | 1998
Luis Valdés; David Alvarez; Esther San José; Pedro Penela; José Manuel Valle; José Manuel García-Pazos; Javier Suárez; Antonio Pose
Chest | 1993
Luis Valdés; Esther San José; David Alvarez; Alfredo Sarandeses; Antonio Pose; Benilda Chomón; José Manuel Álvarez-Dobaño; Marcelino Salgueiro; José Suárez
Chest | 1996
Luis Valdés; David Alvarez; José Manuel Valle; Antonio Pose; Esther San José
European Respiratory Journal | 1996
Luis Valdés; E San Jose; David Alvarez; José Manuel Valle